A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
This study is testing a medicine called efgartigimod to see if it helps people with moderate-to-severe Primary Sjögren's Syndrome (pSjD), a disease where the immune system attacks glands that make moisture like saliva and tears. Participants will be divided into two groups: one group gets the real medicine, while the other gets a placebo (a fake treatment). Later, everyone gets the real medicine. The whole study lasts up to about 105 weeks, which is about 2 years.
Eligibility: You need to be at least 18 years old and have specific medical signs like Anti-Ro/SS-A antibodies, which are proteins in the blood. Certain conditions, like fibromyalgia not under control or recent use of certain medicines, might prevent you from joining.
- Study duration is approximately 105 weeks.
- Includes double-blind and open-label treatment phases.
- Eligibility requires specific medical criteria.